Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 8, 2022
U.S. Food and Drug Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in 2022 NEW YORK (August 8, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for read more →
Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference
June 9, 2022
NEW YORK (June 9, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the JMP Securities Life Sciences Conference on Thursday, June 16, 2022 at 2:30 p.m. ET in New York City. read more →
Indaptus Therapeutics to Present at Jefferies Healthcare Conference
June 3, 2022
NEW YORK (June 3, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 12:45 p.m. ET. A live webcast of the presentation read more →
Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors
May 19, 2022
NEW YORK (May 19, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for a Phase 1 clinical trial in patients with advanced solid tumors where currently approved therapies have read more →
Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference
May 18, 2022
NEW YORK (May 18, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 8:30am ET. A live webcast of the read more →
Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022
Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022 NEW YORK (May 12, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for read more →
Indaptus Therapeutics to Present at 2nd Annual Chronic HBV Drug Development
April 20, 2022
NEW YORK (April 20, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, will present at the 2nd Annual Chronic HBV Drug Development Summit taking place from April 25-27, 2022 in Boston, MA. Presentation Details: Title: Driving read more →
Indaptus Therapeutics to Present at Maxim Group 2022 Virtual Growth Conference
March 23, 2022
NEW YORK (March 23, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in a pre-recorded presentation at the Maxim Group 2022 Virtual Growth Conference made available Monday, March 28, 2022 at 9:00 a.m. ET. An audio webcast read more →
Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update
March 21, 2022
NEW YORK (March 21, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for the fourth quarter and year ended December 31, 2021 and provides a corporate update. “We enter 2022 excited about the future for Indaptus as we continue to advance our clinical read more →
Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit
March 17, 2022
NEW YORK (March 17, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, will present and participate in a panel discussion at the 3rd Annual STING & TLRTargeting Therapies Summit taking place virtually from March 22-24, read more →
© 2021. Indaptus Therapeutics. All Rights Reserved. |